PD-L1 expression in tumors or tumor-associated immune cells (TAICs) assessed by immunohistochemistry (IHC) is the predictive biomarker evaluated in clinical trials, and is currently used in the clinical setting to select patients who may benefit from these therapies [2]. This evidence concerns the gene CD274 and neoplasm.